Intensive management of diabetes pays fewer dividends as patients age and raises the chances of hypoglycemia. But many people ...

Pharma group Hikma looks to take advantage as Novo Nordisk’s Wegovy and Ozempic start to go off patent next year ...

A new study presented at the American Academy of Orthopedic Surgeons meeting reveals the need to stop taking GLP-1 agonists ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

The global anorexiant market is set for significant expansion, with a projected compound annual growth rate (CAGR) of 5.1% over the forecast period, according to a recent study by Future Market ...

Bacterial vaginosis affects nearly a third of women worldwide and can cause infertility, premature births and newborn deaths.

Blockbuster GLP-1 medications are changing patient care, impacting surgery volumes and reshaping the financial landscape of the healthcare industry.

Hikma launched liraglutide, a generic version of an earlier Novo Nordisk weight loss drug, in the US in December. Liraglutide, which Novo sells as Victoza for diabetes and Saxenda for weight loss, has ...

Some patients received Novo Nordisk's Ozempic (semaglutide) or the company's older Victoza (liraglutide). Several other drugs in the class, also known for its weight-loss effects, were used in the ...

Also, so did another GLP-1 compound called liraglutide, which is sold under the brand names Victoza and Saxenda. The Victoza version, the version that's used for diabetes, also recently went generic.

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to ...

G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...